Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 4/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075594 | 0.92 | RORC (0.45) | RORCFAAHEPHX2CNR2CNR1 | |
| SCHEMBL5800624 | 0.90 | SCN9A (0.41) | HTTRECQLSCN9ARORCCHRNA7 | |
| SCHEMBL4079204 | 0.87 | RORC (0.40) | RORCMAPTFAAHEPHX2CNR2 | |
| SCHEMBL4081960 | 0.85 | ACHE (0.39) | RORCACHEFAAHEPHX2CNR2 | |
| SCHEMBL29575091 | 0.84 | CNR1 (0.48) | ACHEFAAHEPHX2CNR1 | |
| SCHEMBL4077473 | 0.84 | CNR1 (0.48) | ACHEFAAHEPHX2CNR1 | |
| SCHEMBL4085186 | 0.83 | CNR1 (0.40) | FAAHEPHX2CNR2CTSSCNR1 | |
| SCHEMBL4085218 | 0.80 | FAAH (0.44) | SCN9ARORCFAAHCNR2CNR1 | |
| SCHEMBL5801936 | 0.78 | RBP4 (0.38) | FAAHEPHX2CNR2CNR1 | |
| SCHEMBL4083772 | 0.78 | FAAH (0.49) | FAAHCNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620395-B1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RES LTD (GB) | 2009-12-30 | — | — | EP | claimed |
| US-7504522-B2 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMITED (GB) | 2009-03-17 | — | — | US | claimed |
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMAITED (GB) | 2007-03-08 | — | — | US | claimed |
| US-20240000748-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | ANEBULO PHARMACEUTICALS, INC. | 2024-01-04 | — | — | US | disclosed |
| WO-2022109043-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | ANEBULO PHARMACEUTICALS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220151990-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | ANEBULO PHARMACEUTICALS, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220151990-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | ANEBULO PHARMACEUTICALS, INC. | 2022-05-19 | — | — | US | disclosed |
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | ANEBULO PHARMACEUTICALS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | ANEBULO PHARMACEUTICALS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| EP-1620395-B1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RES LTD (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-7504522-B2 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMAITED (GB) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | CNR1, CNR2, GPR119 | HTT 2206/4885RECQL 4313/4885SCN9A 216/4885 |
| US-20240000748-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | CNR1, CNR2, FAAH | HTT 1596/4885RECQL 4057/4885SCN9A 611/4885 |
| US-20220151990-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | CNR1, CNR2, FAAH | HTT 1596/4885RECQL 4057/4885SCN9A 611/4885 |
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | CNR1, CNR2, FAAH | HTT 1596/4885RECQL 4057/4885SCN9A 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.